This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: M33.1 (other dermatomyositis) | Special Copayment Reduction: V137 (rare disease) |
| B. Synonyms | Other dermatomyositis |
| C. Adult onset | Likelihood of first onset in adulthood very high — adult dermatomyositis (M33.1, other dermatomyositis) by definition mainly includes subtypes with onset in adults (mainly in their 40s~60s). The median age at onset is about 45~55 years, and childhood onset is classified separately (M33.0). Because the risk of cancer-associated dermatomyositis increases especially at the second onset peak in the 50s~60s, malignancy screening is essential in adult patients at first presentation. Female:male = about 2~3:1. |
| 1. History | 1863 Wagner, 1887 Unverricht early descriptions → 1891 Hepp named dermatomyositis → 1916 Steinert described the adult form → 1975 Bohan-Peter classification criteria → 2004 concept of clinically amyopathic dermatomyositis (CADM) established → 2017 EULAR/ACR classification criteria → 2022 ENMC updated IIM classification. |
| 2. Causes | Small-vessel autoimmune vasculopathy, type I interferon hyperactivity and complement C5b-9-mediated vascular injury are central. Genetic predisposition (HLA-DRB1*0301), association with malignancy (anti-TIF1γ, anti-NXP2, anti-SAE1), ultraviolet light, drugs (statins, anti-PD-1/PD-L1 immune checkpoint inhibitors) and infections act as triggers. Malignancy accompanies about 15~30% of adult dermatomyositis. |
| 3. Genetics | Polygenic. HLA-DRB1*0301 (DR3) and HLA-DQA1*0501 are the main susceptibility alleles. HLA associations by MSA: anti-Jo-1–HLA-DR3, anti-Mi-2–HLA-DR7, anti-TIF1γ–cancer-associated. IRF5 and STAT4 polymorphisms contribute to IFN signaling hyperactivity. Multiple susceptibility loci identified in GWAS. Immune checkpoint inhibitor-related dermatomyositis arises from drug-immune interaction. |
| 4. General epidemiology | Incidence about 5~10/million/year. Prevalence about 10~20/100,000. Female:male = about 2~3:1. Two onset peaks: childhood (JDM) and adults in their 40s~60s. Cancer-associated dermatomyositis is about 15~30% of adult DM; most occur within 1~3 years before or after cancer diagnosis. Korean Special Copayment Reduction V137 (polymyositis/dermatomyositis group). |
| 5. Pathophysiology | Small-vessel autoimmune vasculopathy: complement C5b-9 deposition → capillary loss → muscle ischemia and atrophy (perifascicular atrophy). Type I interferon hyperactivity (pDC activation). Skin: perivascular CD4+ T cell infiltration, endothelial MHC II expression, basement membrane damage. Cancer-associated mechanism: cross-reactivity of the immune response to tumor antigens (TIF1γ, NXP2). |
| 6. Symptoms | Proximal muscle weakness (symmetric), heliotrope rash, Gottron papules/sign, V-sign, shawl sign, cutaneous vasculitis, photosensitivity. Interstitial lung disease (ILD, associated with anti-Jo-1, anti-MDA5, anti-PL-7), dysphagia, arthralgia. Clinically amyopathic dermatomyositis (CADM): skin + ILD without muscle symptoms. Cancer-associated: abrupt onset, treatment resistance. |
| 7. Signs | Heliotrope rash (upper eyelids), Gottron papules (finger joints), nailfold capillary abnormalities, mechanic's hands, proximal muscle weakness, elevated CK/LDH, ANA and MSA positivity, reduced lung function (ILD), muscle edema on MRI. Cancer-associated DM: concurrent cancer-specific symptoms. |
| 8. Screening | No general population screening. Malignancy screening at diagnosis of dermatomyositis (especially adults): CT (chest, abdomen, pelvis), upper endoscopy, colonoscopy, mammography, PET-CT. MSA panel (anti-TIF1γ, anti-NXP2, anti-SAE1, anti-MDA5, anti-Jo-1, anti-Mi-2) testing. Pulmonary function tests and chest HRCT. Intensified monitoring for acute ILD if anti-MDA5 positive. |
| 9. Diagnosis | 2017 EULAR/ACR classification criteria (adult form). Proximal muscle weakness + skin findings (heliotrope rash, Gottron papules, Gottron sign) + supporting criteria (muscle enzymes, MRI, EMG, muscle biopsy). Muscle biopsy: perivascular inflammation, vascular C5b-9 deposition, perifascicular atrophy, MHC-I overexpression. In adults, the presence of accompanying malignancy must be checked. |
| 10. Treatment | High-dose corticosteroids (1mg/kg/day) + steroid-sparing agents (MTX, AZA, MMF). IVIG (2g/kg/cycle): effective for skin and muscle lesions and ILD. Refractory disease and ILD: rituximab, cyclophosphamide, cyclosporine, tacrolimus. Cancer-associated DM: treatment of the primary tumor takes priority. Targeted therapy inhibiting IFN (JAK inhibitors: baricitinib, ruxolitinib) under study. HCQ used as an adjunct for skin lesions. |
| 11. Prognosis | 5-year survival about 75~90% (lower in cancer-associated DM). Main causes of death: interstitial lung disease (acutely progressive), tumor complications, infection (related to immunosuppressive treatment), aspiration pneumonia from dysphagia. Anti-MDA5 antibody positive + rapidly progressive ILD: the subtype with the poorest prognosis. Early diagnosis, aggressive treatment and tumor treatment are key determinants of prognosis. |
| 12. Prevention | Sun protection (SPF 50+ daily), continued HCQ, smoking cessation, infection prevention (up-to-date vaccinations, caution with live vaccines), regular tumor screening (especially if anti-TIF1γ or anti-NXP2 positive), management of steroid adverse effects (osteoporosis, blood glucose, lipids), continued physical therapy and rehabilitation, regular ILD monitoring (pulmonary function, HRCT), and early recognition of myositis symptoms in patients receiving immune checkpoint inhibitors. |
| 13. References | Lundberg IE et al. 2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies. Ann Rheum Dis. 2017 … and 9 other papers |
The historical description of dermatomyositis (DM) begins in mid-19th-century German medicine. The report in 1863 by the German physician Ernst Leberecht Wagner of an inflammatory case with muscle involvement is recognized as the first clinical description, and in 1886~1887 Heinrich Unverricht contributed to establishing the clinical identity of this disease by systematically describing the characteristic syndrome in which skin and muscle are involved simultaneously. In 1891, the German physician Hepp formally used the term 'Dermatomyositis', establishing the modern medical name.
In the early 20th century, more systematic descriptions of the clinical features of adult dermatomyositis were made. In 1916, Steinert and several subsequent researchers precisely described the combined clinical picture of muscle weakness, skin rash and systemic symptoms. With the introduction of corticosteroids in the 1940s, dermatomyositis began to be recognized as an autoimmune disease responsive to immunosuppressive treatment, and treatment response was also used as indirect evidence confirming the diagnosis.
The most important turning point in the history of classification criteria was the classification criteria for inflammatory myopathy published by Bohan and Peter in 1975. These criteria consisted of 5 items — ① proximal muscle weakness, ② elevated muscle enzymes, ③ electromyographic abnormalities, ④ muscle biopsy abnormalities, and ⑤ characteristic skin findings — and were used as the standard for clinical research for about 30 years thereafter. Since the 1990s, the discovery and characterization of myositis-specific antibodies (MSA) brought revolutionary change to the understanding of clinical subtypes of dermatomyositis. As anti-Jo-1 antibody (1980s), anti-Mi-2 antibody, anti-MDA5 antibody (2005), anti-TIF1γ antibody (2006), anti-SAE1 antibody and others were discovered in succession, it became clear that each MSA type is strongly associated with a specific clinical phenotype, prognosis and cancer association.
In 2004, Sato et al. established the concept of clinically amyopathic dermatomyositis (CADM), in which skin lesions and interstitial lung disease are the main manifestations without muscle involvement, and it was later found to be strongly associated with anti-MDA5 antibody. In 2017, EULAR/ACR published new classification criteria for adult and juvenile idiopathic inflammatory myopathies, introducing a probability-based classification model depending on whether a muscle biopsy is available. In 2022, the ENMC (European Neuromuscular Centre) published an updated classification and nomenclature of IIM, further refining the definitions of the major IIM subtypes, including adult dermatomyositis. As immune checkpoint inhibitor (ICI, anti-PD-1/PD-L1 antibody) treatment spreads, immune checkpoint inhibitor-related dermatomyositis is emerging as a new clinical problem.
In Korea, registry studies and development of treatment guidelines for inflammatory myopathies such as dermatomyositis are being carried out, centered on the Korean College of Rheumatology, and it is managed as a rare disease through the National Health Insurance Special Copayment Reduction (V137, polymyositis/dermatomyositis group).
Adult dermatomyositis (DM, M33.1) is a multifactorial autoimmune disease with small-vessel autoimmune vasculopathy at its pathophysiological core. Genetic predisposition, immune dysregulation, environmental factors, drugs and malignancy are jointly involved in its development.
Immunological causes: Hyperactivation of type I interferon (IFN-α/β) and complement-mediated vascular injury are the core immune mechanisms of DM. Type I IFN produced in large amounts by activated plasmacytoid dendritic cells (pDC) leads to vascular endothelial cell damage, loss of small-vessel capillaries within muscle, and activation of CD4+ T cells and B cells. Activation of the classical complement pathway and vascular deposition of C5b-9 (membrane attack complex, MAC) cause damage to endothelial cells of venules and capillaries. Autoreactive CD4+ T cells and B cells induce immune responses targeting muscle, skin and vessel walls, and various myositis-specific antibodies (MSA) act as by-products of immune activation or as direct pathogenic mediators.
Association with malignancy: In adult dermatomyositis, accompanying malignancy is one of the most important clinical features. Malignancy accompanies about 15~30% of adult DM, mostly found within 1~3 years before or after the diagnosis of dermatomyositis. The most commonly associated cancers are ovarian, lung, gastric, colorectal, breast and nasopharyngeal cancers and lymphoma, with some differences according to geographic and ethnic characteristics (e.g., a high proportion of nasopharyngeal cancer in Asia). In cancer-associated DM, the immune response to tumor antigens (TIF1γ, NXP2, etc.) is understood to induce dermatomyositis through cross-reactivity with self-antigens. The clinical observations that dermatomyositis improves after tumor treatment and relapses when the tumor recurs support this association.
Drug-induced dermatomyositis: Dermatomyositis can occur as an immune-related adverse event (irAE) caused by immune checkpoint inhibitors (ICI; anti-PD-1: nivolumab, pembrolizumab; anti-PD-L1: atezolizumab; anti-CTLA-4: ipilimumab). ICI-related dermatomyositis is characterized by CK elevation and proximal muscle weakness, and the skin rash is sometimes more atypical than in typical DM. In patients taking statins, anti-HMGCR antibody-positive immune-mediated necrotizing myopathy (IMNM) occurs, which is a separate subtype distinct from dermatomyositis. Hydroxyurea, D-penicillamine and drugs related to complement gene variants can also cause DM-like syndromes.
Environmental factors: Ultraviolet exposure is associated with worsening of skin lesions, and some studies report an association between latitudes with strong ultraviolet radiation and the prevalence of dermatomyositis. Infections such as EBV, influenza and parvovirus B19 have been proposed as environmental triggers, and molecular mimicry in particular has been proposed between specific MSAs (anti-Jo-1 antibody and histidyl-tRNA synthetase).
Adult dermatomyositis (DM) follows a complex polygenic inheritance pattern, and the HLA gene cluster is the most important genetic susceptibility factor. Non-HLA genes, HLA associations with myositis-specific antibodies, and the genetic background of immune checkpoint inhibitor-related DM are also important areas of research.
HLA associations: HLA-DRB1*0301 (DR3) and HLA-DQA1*0501 are the main susceptibility genotypes for adult DM across several ethnic groups. HLA-DRB1*0701 (DR7) is particularly associated with anti-Mi-2 antibody-positive DM. HLA-DQA1*0501 is a susceptibility factor widely reported in both adult and juvenile DM and is also associated with the production of specific MSAs. In anti-Jo-1 antibody positivity (antisynthetase syndrome), HLA-DRB1*0301 (DR3) and HLA-DQA1*0501 are strongly associated, and there are reports that the HLA-DQA1*03 group is associated with anti-TIF1γ antibody-positive DM.
Non-HLA susceptibility genes: IRF5 (interferon regulatory factor 5) polymorphisms are directly associated with type I IFN hyperactivity and are reported as susceptibility factors in DM and other IIMs. STAT4 polymorphisms also contribute to DM susceptibility through the IFN signaling pathway and T cell activation. BLK, PTPN22 and TNFAIP3 polymorphisms are genetic risk factors shared with other autoimmune diseases such as SLE and RA, and associations have also been reported in DM. There are reports that the TNF-α -308A allele is associated with a severe course of DM, especially calcinosis.
Myositis-specific antibodies (MSA) and genetic associations: Each MSA has a distinctive clinical phenotype and HLA association. Anti-Jo-1, anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-KS (antisynthetase antibody group): anti-Jo-1 is the most common (about 20% of adult IIM) and is associated with antisynthetase syndrome (ILD, arthritis, mechanic's hands, fever, Raynaud phenomenon). Strongly associated with HLA-DR3. Anti-Mi-2 antibody: associated with typical DM skin findings (heliotrope, Gottron, V-sign), good treatment response; HLA-DR7 association. Anti-TIF1γ antibody (anti-p155/140): a strong predictor of cancer-associated DM in adults (positive in about 50~60% of cancer-associated DM). Anti-NXP2 antibody: associated with calcinosis, vasculitis and severe muscle involvement; possible cancer association in adults. Anti-SAE1 antibody: associated with dysphagia and extensive skin involvement. Anti-MDA5 antibody: associated with CADM (clinically amyopathic dermatomyositis) + skin ulcers + acute ILD; especially frequent in Asians, with a high risk of rapidly progressive ILD.
Genetics of immune checkpoint inhibitor-related DM: Development of DM after ICI administration is associated with autoimmune T cell activation due to blockade of the PD-1/PD-L1 pathway. Detection of MSAs such as anti-TIF1γ has also been reported in ICI-related myositis, and studies are under way on whether HLA genotype may be associated with the risk of ICI-related autoimmune reactions.
Adult dermatomyositis (DM, M33.1) is a rare autoimmune disease worldwide, with epidemiological differences by race, sex, age and geographic location. Overall, incidence is high in middle-aged women, and the occurrence of cancer-associated dermatomyositis poses an important clinical challenge in adult care.
Incidence and prevalence: The annual incidence of adult dermatomyositis is reported at about 5~10 per million population. The annual incidence of all idiopathic inflammatory myopathies (IIM) is about 10~20 per million population, of which adult dermatomyositis accounts for about 30~40%. Prevalence is estimated at about 10~20 per 100,000 population. There is regional variation, with higher incidence reported in some regions of Asia and Africa. Studies in the United States and Europe report a tendency for higher incidence and a more severe course in Black and Hispanic patients than in White patients.
Sex and age distribution: The female:male ratio is about 2~3:1, with the highest incidence in middle age (40s~60s). Dermatomyositis typically has two onset peaks: childhood (5~14 years, JDM) and adulthood (40s~60s). In adult-onset DM, onset before the 40s is relatively rare, and onset after the 60s is also reported, but in this age group the likelihood of cancer-associated DM is higher. Studies show that male DM has a higher proportion of cancer association than female DM.
Epidemiology of cancer-associated dermatomyositis: Malignancy accompanies about 15~30% of adult DM, corresponding to a cancer risk about 5~7 times higher than in the general population. In anti-TIF1γ antibody-positive patients, the cancer-associated risk is even higher, with malignancy reported in about 50~70%. Cancer diagnoses cluster within 1~3 years before or after the DM diagnosis, and ovarian cancer (especially in women), lung cancer, gastric cancer, colorectal cancer and breast cancer are the most common. In Asian patients, the frequency of nasopharyngeal cancer is relatively high.
Increase in immune checkpoint inhibitor-related DM: As immune checkpoint inhibitor (ICI) treatment is extended to various malignancies, the occurrence of ICI-related inflammatory myopathies (especially dermatomyositis and necrotizing myopathy) is increasing. The incidence of ICI-related myositis is reported at about 1~3% of ICI-treated patients, and because severe ICI-related myositis has high mortality, early recognition and treatment are important.
Epidemiology in Korea: In Korea, the combined annual incidence of DM and polymyositis (PM) is estimated at about 0.5~1 per 100,000 population, and studies based on National Health Insurance data confirm that women and the middle-aged are the main affected groups. In Korea, DM is registered and managed under Special Copayment Reduction V137 (polymyositis/dermatomyositis group). In Korean DM patients as well, acute ILD of the anti-MDA5-positive subtype is an important clinical challenge, and given the characteristics of the Asian region, attention is also needed for nasopharyngeal cancer-associated DM.
The pathogenesis of adult dermatomyositis is summarized as a cascade centered on small-vessel autoimmune vasculopathy: type I interferon hyperactivity, complement-mediated vascular injury, tissue infiltration by autoreactive immune cells, and muscle ischemia and atrophy. The mechanisms of muscle pathology and skin pathology have similarities and differences, and in cancer-associated DM an additional immune cross-reactivity mechanism is involved.
Central role of the type I interferon axis: The most consistent molecular pathogenic feature of dermatomyositis is hyperactivity of type I IFN (IFN-α, IFN-β) signaling. Widespread overexpression of interferon-stimulated genes (ISG) is observed in patients' blood, skin and muscle tissue. Plasmacytoid dendritic cells (pDC) recognize apoptotic nucleic acids via TLR7 and TLR9 and secrete large amounts of IFN-α. This IFN-α damages vascular endothelial cells, amplifies immune cell activation and upregulates expression of MHC I molecules on muscle fibers. Anifrolumab and JAK inhibitors are currently being studied and applied as treatments targeting this pathway.
Complement-mediated vascular injury and muscle ischemia: The most characteristic pathological finding in dermatomyositis muscle biopsies is deposition of C5b-9 (membrane attack complex, MAC) in small intramuscular vessels (venules, capillaries). This indicates activation of the classical complement pathway on vascular endothelial cells, resulting in capillary loss and muscle ischemia. Reduced vascular density is directly associated with perifascicular atrophy. This mechanism is a feature unique to DM, in contrast to polymyositis, in which direct attack on muscle fibers by CD8+ T cells predominates.
Mechanism of skin lesions: The histopathology of DM skin lesions (heliotrope rash, Gottron papules) consists of perivascular infiltration of CD4+ T cells and plasmacytoid dendritic cells, vacuolar interface change, basement membrane thickening and mucin deposition. Type I IFN signaling is also activated in keratinocytes and fibroblasts, and ultraviolet exposure amplifies type I IFN production through keratinocyte death and worsens skin lesions. Increased expression of MHC II+ endothelial cells is observed in skin lesions, and nailfold capillary abnormalities serve as a window onto the systemic vasculopathy.
Mechanism of cancer-associated dermatomyositis: In cancer-associated DM, the antitumor immune response to antigens expressed by tumor cells (especially TIF1γ, NXP2) is understood to cause cross-reactivity (or molecular mimicry) with similar antigens also expressed in self tissues (muscle, skin). In particular, TIF1γ is expressed in normal muscle and skin and is also known to function as a tumor suppressor. The clinical pattern of improvement of dermatomyositis after tumor treatment and re-exacerbation of dermatomyositis upon tumor recurrence supports this cross-reactive immune mechanism.
Mechanism of immune checkpoint inhibitor-related dermatomyositis: PD-1/PD-L1 blockade lowers the activation threshold of autoreactive T cells, causing autoimmune tissue damage. Increased type I IFN signaling and muscle and skin autoimmunity are also observed in ICI-related DM. In this case, differentiation from anti-HMGCR antibody- or anti-SRP antibody-positive immune-mediated necrotizing myopathy (IMNM) is needed.
The clinical symptoms of adult dermatomyositis consist of muscle involvement, skin involvement, systemic symptoms, and multisystem involvement of the lungs, heart, joints and other organs. The range and severity of symptoms differ among patients, and clinical subtypes are distinguished by myositis-specific antibody (MSA) type.
Muscle symptoms: Proximal symmetric muscle weakness is the core clinical symptom of DM. The shoulder girdle and pelvic girdle muscles and the neck flexor muscles are mainly involved. Climbing stairs, rising from a chair and raising the arms overhead become difficult, and head drop may occur due to neck flexor weakness. Pharyngeal muscle involvement causes dysphagia and dysarthria and is a risk factor for aspiration pneumonia. Respiratory muscle involvement (diaphragm, intercostal muscles) is rare but can cause respiratory failure. Myalgia and tenderness accompany about 50~70%. Clinically amyopathic dermatomyositis (CADM) is a subtype in which skin lesions and interstitial lung disease are present but muscle weakness is absent or very mild.
Skin symptoms: Heliotrope rash: violaceous to purple erythema of both upper eyelids, photosensitive and highly specific for DM. Gottron papules: pink to violaceous papules or plaques on the dorsal finger joints. Gottron sign: erythema over the dorsal knee, elbow and ankle joints. V-sign: photosensitive erythema of the neck and upper chest (V-shaped area). Shawl sign: erythema of the shoulders and upper back. Mechanic's hands: fissuring, hyperkeratosis and roughness of the lateral fingers and palms, especially prominent in antisynthetase syndrome. Scalp rash and alopecia. Cutaneous vasculitis and skin ulcers (prominent in anti-MDA5 positivity). Lipodystrophy and calcinosis (rare in adult DM but possible). Photosensitivity: skin worsening after UV exposure.
Pulmonary symptoms (interstitial lung disease, ILD): ILD is one of the most important organ complications in adult DM, occurring in about 20~50%. The risk of ILD is especially high in patients positive for anti-Jo-1 antibody (and other antisynthetase antibodies) or anti-MDA5 antibody. It presents with cough, dyspnea and exertional dyspnea, and in the acutely progressive form (anti-MDA5 positive) it can deteriorate rapidly within weeks to months and lead to death. Crackles (velcro crackles) may be heard on chest auscultation.
Joint symptoms: Arthralgia and arthritis accompany about 30~50%, mainly as non-deforming polyarthritis. Arthritis is prominent in antisynthetase syndrome. Raynaud phenomenon is also observed in about 20~30%.
Systemic and other symptoms: Fever, fatigue and weight loss are common early. Cardiac involvement (myocarditis, pericarditis, conduction disturbances) is rare but can occur in severe DM. Gastrointestinal involvement (esophageal dysmotility, dysphagia) is associated with pharyngeal and esophageal muscle weakness.
The physical signs of adult dermatomyositis are identified through muscle strength testing, skin examination, lung auscultation, joint examination, etc., and change with activity and course.
Muscle strength testing: Proximal muscle strength (shoulder abduction, elbow flexion, hip flexion, knee extension, etc.) is quantified by standardized manual muscle testing (MMT). Early on, strength may appear preserved, but as the disease progresses the MMT-8 score decreases. In severe cases, inability to rise from a supine position, gait instability and head drop are observed. Myalgia is confirmed as muscle tenderness on palpation.
Skin signs: Heliotrope rash: violaceous to purple erythema of the upper eyelids, possibly with edema. Gottron papules: pink to violaceous papules over the dorsal finger joints (MCP, PIP, DIP), possibly with scale. Gottron sign: erythematous lesions on the extensor surfaces of the knees and elbows. V-sign, shawl sign: erythema in sun-exposed areas. Mechanic's hands: hyperkeratosis and fissuring of the lateral fingers and palms (antisynthetase syndrome). Nailfold capillaroscopy findings: dilated capillary loops, irregular loops, hemorrhages, avascular areas. These are noninvasive markers of small-vessel vasculopathy associated with DM activity.
Pulmonary signs: With ILD, crackles (fine inspiratory crackles, velcro rales) are heard at both lung bases. Pulmonary function tests show a restrictive pattern (reduced FVC and TLC, reduced DLCO). Oxygen desaturation (at rest or with exercise) may be observed.
Main laboratory findings: Muscle enzymes: elevated CK, LDH, AST, ALT and aldolase. CK may be relatively lower in DM than in PM. Muscle enzymes may be normal in CADM. ANA: positive in about 70~80% (mainly low titer). MSA: anti-Mi-2 (classic DM phenotype), anti-TIF1γ (cancer-associated), anti-MDA5 (CADM, ILD, skin ulcers), anti-NXP2 (muscle involvement, calcification), anti-SAE1 (dysphagia, skin), etc. Antisynthetase antibodies (anti-Jo-1, etc.): antisynthetase syndrome. Elevated ESR and CRP. Cytopenias (rarely). Aldolase is useful for reflecting DM activity even when CK is normal.
Imaging findings: MRI (T2 STIR): intramuscular edema (high signal), fascial inflammation, fatty infiltration (chronic phase). Chest HRCT: ILD evaluation (NIP, OP, DIP, UIP patterns). Plain X-ray: calcinosis (rarely). Echocardiography: evaluation of myocardial involvement and pericardial effusion.
General population screening for adult dermatomyositis is not recommended. However, the most important screening task at diagnosis of adult DM is to determine whether malignancy is present. A systematic testing approach after suspicion and confirmation of DM prevents diagnostic delay and missed tumor detection.
Initial screening when DM is clinically suspected: In adults, DM is suspected and tested for when the following are present: proximal muscle weakness (progressing over weeks to months), characteristic skin findings of heliotrope rash or Gottron papules/sign, and unexplained elevation of CK and LDH. In this case, initial screening tests are performed, including a muscle enzyme panel (CK, LDH, AST, ALT, aldolase), ANA, an MSA panel, complete blood count (CBC), ESR, CRP, liver and kidney function tests, and thyroid function tests (to differentiate DM-like hypothyroidism).
Malignancy screening — the top priority in adult DM: At diagnosis of adult DM (especially age 40 or older), accompanying malignancy must be screened for. Because the cancer-associated risk is higher in patients positive for anti-TIF1γ antibody, anti-NXP2 antibody (adults) or anti-SAE1 antibody, intensive screening is needed. Basic screening: chest, abdominal and pelvic CT, upper endoscopy, colonoscopy, and in women mammography + ultrasound and gynecologic ultrasound or MRI. Additional screening (when risk is high or basic screening is negative): PET-CT (search for metabolically active lesions throughout the body), serum tumor markers (CA-125, CEA, CA19-9, etc.). Consider the risk of nasopharyngeal cancer in Asian patients (EBV-related testing). Some guidelines recommend annual rescreening for up to 3 years after onset even if initial screening is negative.
Screening for interstitial lung disease (ILD): In all adult DM patients, pulmonary function tests (FVC, DLCO) and chest HRCT are included in the initial evaluation regardless of respiratory symptoms. Especially in patients positive for anti-MDA5 antibody or anti-Jo-1 antibody, early aggressive pulmonary evaluation and monitoring are essential. Because acute ILD in anti-MDA5-positive patients can progress rapidly within weeks, starting aggressive treatment through pulmonology consultation immediately upon diagnosis is decisive for prognosis.
Cardiac screening: Baseline echocardiography (evaluation of myocarditis, pericardial effusion, pulmonary hypertension) and electrocardiography are performed. Consider the possibility of myocarditis if cardiac enzymes (troponin) are elevated. In elderly patients, assess thrombotic risk with antiphospholipid antibody testing.
The diagnosis of adult dermatomyositis is made by integrating clinical features, serology, imaging, electrophysiology and histopathology, and the 2017 EULAR/ACR classification criteria are currently used as the standard. Evaluation for cancer association and classification of clinical subtypes by MSA are especially important in adult care.
2017 EULAR/ACR classification criteria (adults): These criteria are a probability-based model that applies different variable weights depending on whether a muscle biopsy has been performed. Entry criterion: age at onset ≥18 years (adult IIM classification). Examples of clinical variables: age at onset ≥40 years (+1.4 points), proximal muscle weakness (+0.7 points), heliotrope rash (+3.1 points), Gottron papules (+2.0 points), Gottron sign (+1.2 points), V-sign or shawl sign (+1.5 points), cough (+0.7 points), arthritis (+0.7 points), renal involvement (-1.0 points — inconsistent with IIM), elevated CK/LDH (+1.3 points), abnormal muscle MRI (+1.2 points). With muscle biopsy: perifascicular atrophy (+1.4 points), perivascular inflammation (+1.7 points), vascular C5b-9 deposition (+1.7 points), MHC-I overexpression on muscle fibers (+1.5 points), etc. provide additional weight. According to the total score, the likelihood of DM is classified as high, intermediate or low.
Muscle biopsy: Muscle biopsy is essential when MSA are negative, the clinical picture is atypical, or differentiation from other diseases is needed. The specimen is obtained under MRI guidance from an active site (muscle with high T2 STIR signal). DM-specific pathology: perivascular inflammation (CD4+ T cells, B cells, pDC), vascular C5b-9 deposition (immunohistochemistry), perifascicular atrophy, MHC-I overexpression on muscle fibers, with little typical necrosis. In anti-MDA5-positive CADM, the muscle biopsy may be normal or show only mild abnormalities.
Myositis-specific antibody (MSA) panel: MSA panel testing is essential for classifying clinical subtypes, predicting the risk of organ involvement (ILD, cancer) and planning treatment. Anti-Mi-2: classic DM, good treatment response. Anti-TIF1γ (anti-p155/140): marker of high risk for cancer-associated DM (adults). Anti-NXP2 (anti-MJ): calcification and severe muscle involvement in adults, possible cancer association. Anti-MDA5: CADM + skin ulcers + ILD (risk of acute progression). Anti-SAE1: dysphagia, extensive skin involvement. Antisynthetase antibody group (anti-Jo-1, PL-7, PL-12, etc.): antisynthetase syndrome (ILD + arthritis + mechanic's hands).
Differential diagnosis: Differentials include polymyositis (PM: direct infiltration of muscle fibers by CD8+ T cells, little vascular injury), immune-mediated necrotizing myopathy (IMNM: anti-HMGCR or anti-SRP antibody positive, marked CK elevation), inclusion body myositis (IBM: gradual progression without delay, frequent in men over 60, reticular degenerating fibers), overlap syndromes (anti-U1RNP: MCTD, anti-Scl-70: SSc overlap), drug-induced myopathy (statins, colchicine, steroid myopathy), infectious myositis and malignancy-related myopathy.
The treatment goals in adult dermatomyositis are recovery of muscle strength, improvement of skin lesions, stabilization or improvement of ILD, improvement of quality of life and minimization of steroid-related adverse effects. In cancer-associated DM, treatment of the primary tumor is most important. Treatment is individualized according to disease severity, MSA type and organ involvement.
Corticosteroids — first-line treatment: Treatment is started with oral prednisolone 1mg/kg/day (maximum 60~80mg/day). In severe cases (severe muscle weakness, dysphagia, acutely progressive ILD, cardiac involvement), intravenous methylprednisolone pulses (500~1,000mg/day × 3 days) are used first. Generally, gradual tapering begins after 4~6 weeks according to clinical response (tapering 10~20% per month), and maintenance treatment spares steroids at the minimum dose. In antisynthetase syndrome-related ILD and anti-MDA5-positive ILD, high-dose steroids must be maintained longer.
Steroid-sparing immunosuppressants: Methotrexate (MTX, 10~20mg/week, oral or subcutaneous): first-line steroid-sparing agent for skin and muscle symptoms. Folic acid supplementation in parallel. Caution for hepatotoxicity and pulmonary toxicity; use with care when ILD is present (pulmonary toxicity may be difficult to distinguish). Azathioprine (AZA, 1.5~2.5mg/kg/day): widely used for maintenance treatment; given after checking TPMT activity. Mycophenolate mofetil (MMF, 2~3g/day): preferred in DM with ILD; also effective for skin lesions. Cyclosporine (3~5mg/kg/day): used in combination with steroids, especially in DM with ILD (anti-Jo-1 or anti-MDA5 positive). Tacrolimus (0.05~0.1mg/kg/day): can be used as an alternative to cyclosporine in DM with ILD.
Intravenous immunoglobulin (IVIG): IVIG (2g/kg/cycle, given over 2~5 days, repeated monthly) is a treatment whose efficacy in DM has been proven in randomized controlled trials. It is effective for muscle and skin lesions and is used especially when steroid-related adverse effects are a concern or a rapid response is needed. It is also used for additional immunosuppression in anti-MDA5-positive acute ILD.
Biologics and targeted therapy: Rituximab (anti-CD20): used for its B cell-depleting effect in refractory DM, especially in MSA-positive (antisynthetase, anti-MDA5, anti-Mi-2) patients. Cyclophosphamide (CTX): given intravenously in acutely progressive ILD (anti-MDA5, antisynthetase positive) and life-threatening DM. JAK inhibitors (baricitinib, ruxolitinib, tofacitinib): improvement of skin disease and ILD through blockade of type I IFN signaling has been reported in small studies and case reports; phase 3 clinical trials in adult IIM are under way. Abatacept (CTLA4-Ig): improvement of muscle symptoms in a phase 3 trial in adult refractory IIM. Combination use with intravenous immunoglobulin has also been studied.
Treatment of cancer-associated DM: Treatment of the malignancy (surgery, chemotherapy, radiotherapy) takes priority, and DM often improves spontaneously after tumor treatment. Immunosuppressive treatment for DM is given concurrently with tumor treatment, and in immune checkpoint inhibitor (ICI)-related DM, the principle is steroid treatment after discontinuing the ICI, while weighing the need for cancer treatment.
The prognosis of adult dermatomyositis differs greatly by clinical subtype, MSA type, organ involvement and presence of malignancy. Overall 5-year survival is about 75~90%, but prognosis is markedly poor in cancer-associated DM and acutely progressive ILD.
Causes of death and prognostic factors: The main causes of death are ① interstitial lung disease (especially anti-MDA5-positive acutely progressive ILD), ② complications of malignancy (cancer-associated DM), ③ serious infections (pneumonia and opportunistic infections related to immunosuppressive treatment), and ④ aspiration pneumonia due to dysphagia. Poor prognostic factors include anti-MDA5 antibody positivity (high risk of acute ILD), accompanying cancer, pharyngeal and respiratory muscle involvement, age 60 or older, delayed diagnosis and poor treatment response. Good prognostic factors include anti-Mi-2 antibody positivity (good treatment response, low cancer risk), early diagnosis and treatment, and MSA-negative moderate DM.
Prognosis of anti-MDA5 antibody-positive DM: Anti-MDA5-positive DM is characterized by interstitial lung disease, skin ulcers, fever and arthritis, and rapid progression of ILD is the most serious prognostic determinant. There are reports that 30~50% of patients with acutely progressive ILD die despite aggressive immunosuppressive treatment (high-dose steroids + cyclosporine + IVIG or CTX in combination). Rapid diagnosis and initiation of aggressive treatment determine survival.
Prognosis of cancer-associated DM: The prognosis of cancer-associated DM is determined mainly by the stage and treatment response of the primary tumor. Prognosis is good when tumors are detected early and curable (e.g., stage I breast cancer, stage I colorectal cancer) and DM shows complete remission after tumor treatment. In contrast, the prognosis is poor in DM accompanied by advanced or metastatic tumors. Early detection of malignancy within the first 1~2 years after DM diagnosis has a positive impact on survival.
Long-term complications and quality of life: In the long term, joint contractures, persistent muscle weakness, calcinosis (rarely), steroid-related complications (osteoporosis, diabetes, hypertension, cataracts, avascular necrosis of bone), respiratory impairment due to chronic ILD, cognitive decline, and depression and anxiety can impair quality of life. Regular multidisciplinary follow-up, rehabilitation and psychological support contribute to improving long-term prognosis.
Primary prevention of adult dermatomyositis (prevention of onset itself) is currently not possible. However, secondary and tertiary prevention strategies that minimize complications after onset (worsening of ILD, failure of early detection of malignancy, steroid-related adverse effects, infection) play a key role in clinical practice.
Sun protection: In DM, ultraviolet light is a major trigger of worsening skin lesions and systemic symptoms. Patients with photosensitive skin lesions use a broad-spectrum sunscreen of SPF 50 or higher that blocks both UVA and UVB daily, and wear UV-protective clothing and hats during outdoor activities. They are educated to refrain from going out between 10 a.m. and 2 p.m., when ultraviolet radiation is strong.
Regular malignancy screening: Regular malignancy screening is maintained for at least 3 years after DM diagnosis. In particular, patients positive for anti-TIF1γ, anti-NXP2 or anti-SAE1 antibodies have a high cancer-associated risk and need intensive screening. Annual CT (chest, abdomen, pelvis), endoscopy, gynecologic examination in women, PET-CT, etc. are performed depending on the clinical situation.
Regular ILD monitoring: In all DM patients, pulmonary function tests (FVC, DLCO) are performed every 6~12 months for early detection and monitoring of progression of ILD, and chest HRCT is performed immediately when new respiratory symptoms develop. For anti-MDA5-positive patients, patient education is strengthened so that they respond immediately to changes in symptoms, and the monitoring interval is shortened.
Infection prevention: In DM patients on immunosuppressive treatment, inactivated vaccines such as influenza, pneumococcal and hepatitis B are kept up to date. Live vaccines are contraindicated in moderate or greater immunosuppression. To prevent Pneumocystis pneumonia (PCP), TMP-SMX prophylaxis is considered in patients using high-dose steroids in combination with immunosuppressants.
Prevention of steroid-related complications: Osteoporosis is prevented with calcium (1,000~1,200mg/day) and vitamin D (600~1,000 IU/day) supplementation and weight-bearing exercise, and in patients on long-term steroids, DEXA bone densitometry and bisphosphonate treatment are considered. Blood glucose, blood pressure and lipids are monitored regularly to manage metabolic complications early.
Physical therapy and rehabilitation: Passive range-of-motion exercises are maintained even in the acute phase, and in remission, active strengthening, cardiopulmonary training and balance exercises are introduced gradually. In patients with dysphagia, a swallowing rehabilitation program by a speech therapist and dietary modification contribute to preventing aspiration pneumonia.
Monitoring of patients receiving immune checkpoint inhibitors: In patients receiving ICIs for cancer treatment, if proximal muscle weakness, characteristic skin findings or CK elevation appear, the possibility of dermatomyositis is considered immediately and the patient is referred to rheumatology. Discontinuation of the ICI and steroid administration are the standard response.
Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955-1964. DOI: 10.1136/annrheumdis-2017-211468. PMID: 28595184.
Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020;16(12):689-701. DOI: 10.1038/s41584-020-00515-9. PMID: 33037394.
Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis. Arthritis Rheum. 2012;64(2):523-532. DOI: 10.1002/art.33379. PMID: 21904999.
Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571-1576. DOI: 10.1002/art.21023. PMID: 15880818.
Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis (RIM study). Arthritis Rheum. 2013;65(2):314-324. DOI: 10.1002/art.37754. PMID: 23124935.
Tanboon J, Uruha A, Stenzel W, Nishino I. Where is dermatomyositis heading? Curr Opin Neurol. 2021;34(5):595-606. DOI: 10.1097/WCO.0000000000000960. PMID: 34224440.
Wang G, Peng Q, Xu J, et al. Effects of therapeutic plasma exchange on anti-MDA5 antibody levels and lung function in patients with rapidly progressive interstitial lung disease associated with dermatomyositis. Clin Rheumatol. 2020;39(4):1219-1227. DOI: 10.1007/s10067-019-04892-z. PMID: 31974846.
Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372(18):1734-1747. DOI: 10.1056/NEJMra1402225. PMID: 25923553.
Hornung T, Ko A, Tüting T, et al. Efficacy of low-dose recombinant interleukin-2 in patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis and rapidly progressive interstitial lung disease. Br J Dermatol. 2019;180(2):416-418. DOI: 10.1111/bjd.17153. PMID: 30079936.
Kim KJ, Park CK, Kim YW, et al. Clinical features and prognosis of Korean patients with dermatomyositis: a retrospective single center study. Korean J Intern Med. 2019;34(5):1092-1101. DOI: 10.3904/kjim.2018.103. PMID: 30392380.